首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   181317篇
  免费   16274篇
  国内免费   7257篇
耳鼻咽喉   2398篇
儿科学   3966篇
妇产科学   2459篇
基础医学   31336篇
口腔科学   5572篇
临床医学   14641篇
内科学   23143篇
皮肤病学   4435篇
神经病学   9949篇
特种医学   4409篇
外国民族医学   118篇
外科学   15547篇
综合类   28761篇
一般理论   5篇
预防医学   6969篇
眼科学   3557篇
药学   14725篇
  84篇
中国医学   6804篇
肿瘤学   25970篇
  2024年   82篇
  2023年   2680篇
  2022年   3544篇
  2021年   5884篇
  2020年   6239篇
  2019年   5555篇
  2018年   5648篇
  2017年   6291篇
  2016年   6411篇
  2015年   7030篇
  2014年   11093篇
  2013年   12286篇
  2012年   10857篇
  2011年   12055篇
  2010年   9838篇
  2009年   9368篇
  2008年   9853篇
  2007年   9934篇
  2006年   9001篇
  2005年   8144篇
  2004年   7197篇
  2003年   6192篇
  2002年   5048篇
  2001年   4328篇
  2000年   3552篇
  1999年   3095篇
  1998年   2531篇
  1997年   2493篇
  1996年   2143篇
  1995年   2166篇
  1994年   1925篇
  1993年   1590篇
  1992年   1309篇
  1991年   1227篇
  1990年   954篇
  1989年   895篇
  1988年   837篇
  1987年   688篇
  1986年   617篇
  1985年   798篇
  1984年   712篇
  1983年   497篇
  1982年   532篇
  1981年   420篇
  1980年   357篇
  1979年   277篇
  1978年   186篇
  1977年   153篇
  1976年   121篇
  1975年   47篇
排序方式: 共有10000条查询结果,搜索用时 14 毫秒
1.
肾脏是人体最重要的排泄器官。肾单元近端小管细胞具有多种药物转运体和代谢酶,在药物及其代谢物处置中发挥关键作用。近端小管细胞中主要转运体包括有机阴离子转运体、有机阳离子转运体、有机阳离子/肉毒碱转运体、多药及毒素外排转运蛋白、P-糖蛋白、乳腺癌耐药蛋白和多药耐药相关蛋白;主要代谢酶包括细胞色素P450酶,UDP-葡萄糖醛酸基转移酶、磺酸基转移酶、谷胱甘肽S-转移酶。肾脏转运体和/或代谢酶介导药物相互作用(DDIs)是临床关注的重要问题。肾脏转运体和代谢酶存在密切协作关系,在肾脏也存在多种相互作用现象(包括转运-转运相互作用,代谢-代谢相互作用和转运-代谢相互作用),其显著影响药物肾脏处置、临床疗效和肾毒性。本文系统阐述了这些相互作用对药物及其代谢物的肾脏排泄、药动学、DDIs和肾毒性的影响。今后需要进一步阐明肾脏转运-代谢相互作用机制,将有助于研究体内药物肾脏处置和DDIs,促进临床合理用药。  相似文献   
2.
3.
近年来肌骨超声迅速发展,研究者对骨关节疾病的研究正逐渐兴起,部分学者已在使用高频超声的基础上联合应用超声造影、剪切波弹性成像、萤火虫技术等方法上对痛风性关节炎患者进行探索。本文就痛风性关节炎显像的一些方法及可以提供一定诊断帮助的血流新技术予以综述及探讨。  相似文献   
4.
5.
《Value in health》2022,25(3):331-339
ObjectivesClinical artificial intelligence (AI) is a novel technology, and few economic evaluations have focused on it to date. Before its wider implementation, it is important to highlight the aspects of AI that challenge traditional health technology assessment methods.MethodsWe used an existing broad value framework to assess potential ways AI can provide good value for money. We also developed a rubric of how economic evaluations of AI should vary depending on the case of its use.ResultsWe found that the measurement of core elements of value—health outcomes and cost—are complicated by AI because its generalizability across different populations is often unclear and because its use may necessitate reconfigured clinical processes. Clinicians’ productivity may improve when AI is used. If poorly implemented though, AI may also cause clinicians’ workload to increase. Some AI has been found to exacerbate health disparities. Nevertheless, AI may promote equity by expanding access to medical care and, when properly trained, providing unbiased diagnoses and prognoses. The approach to assessment of AI should vary based on its use case: AI that creates new clinical possibilities can improve outcomes, but regulation and evidence collection may be difficult; AI that extends clinical expertise can reduce disparities and lower costs but may result in overuse; and AI that automates clinicians’ work can improve productivity but may reduce skills.ConclusionsThe potential uses of clinical AI create challenges for health technology assessment methods originally developed for pharmaceuticals and medical devices. Health economists should be prepared to examine data collection and methods used to train AI, as these may impact its future value.  相似文献   
6.
Since their inception in the 1960s–70s, mesenchymal stem/stromal cells (MSCs) have gained interest because of their differentiation potential, anti-inflammatory effects, and immune-modulating properties. Both cell-based and cell-free MSC treatments show healing capacity in injured tissues. Cell-based treatment comprises MSCs and all secreted products, whereas cell-free treatments include only the secreted products. MSCs are therapeutically administered to many damaged organs owing to their efficacy. Specifically, the eye is a unique organ system to study the effects of MSCs, as treatment is easily applied and measured owing to its external location. The eye holds an immune-privileged status, wherein inflammation and immune responses are innately down-regulated. As excessive inflammation in the cornea often leads to fibrosis and irreversible corneal hazing, many studies have investigated the anti-inflammatory and immune-modulating capacities of MSCs. Decades of research suggest that MSCs modulate the immune response by secreting cytokines, growth factors, and extracellular matrix proteins that inhibit the infiltration of inflammatory cells following injury and promote a healing phenotype via M2 macrophage polarization. MSCs have also shown trans-differentiation potential into cornea-specific cell types during the wound healing process, such as corneal epithelial, stromal, or endothelial cells. This review discusses recent investigations of MSC treatment in the cornea, focusing on therapeutic efficacy, mechanisms, and future directions.  相似文献   
7.
目的探讨辅助生殖技术中女方经阴道超声取卵手术导致泌尿系损伤的临床特点及诊断、处理措施。方法回顾性分析广西壮族自治区生殖医院2012年至2020年辅助生殖技术女方取卵手术中发生泌尿系损伤的临床资料、疾病类型、发现时机、诊治情况、预后及处理措施。结果 44 144例取卵手术中,发生泌尿系损伤20例,发生率为0.045%。其中膀胱损伤19例,输尿管损伤1例。在膀胱损伤中,术中发现1例,术后发现18例,输尿管损伤为术后发现。其中有8例是在进行了胚胎移植术后才发现,最终有4例获得妊娠。全部的病例经对症处理、膀胱冲洗和(或)膀胱镜检查、止血等治疗后,均痊愈。结论在辅助生殖技术中女方取卵手术损伤虽小,但要注意防范泌尿系损伤发生的风险,及时发现并处理,利于辅助生殖技术的后续治疗。  相似文献   
8.
9.
《Clinical lung cancer》2022,23(6):467-476
BackgroundImmune checkpoint inhibitor (ICI) monotherapy is more effective than cytotoxic chemotherapy in improving overall survival (OS) among patients with advanced-stage non-small cell lung cancer (NSCLC). Recently, chemotherapy combined with ICI has been found to yield good outcomes. However, ICI monotherapy is still considered an important treatment option. Data on long-term progression-free survival (PFS) and OS in real-world settings are limited.Patients and MethodsThis was a multicenter retrospective observational study. A total of 435 consecutive patients histologically diagnosed with advanced, metastatic, or recurrent NSCLC treated with ICI monotherapy were enrolled in this study from December 2015 to December 2018. Clinical data were collected from electronic medical records and pharmacy databases.ResultsThe PFS and OS of the patients were 3.4 and 13.0 months, respectively. The objective response and disease control rates were 22.8% and 54.9%, respectively, and the 4-year survival rate was 17.9%. Multivariate analyses revealed that elder patients (>70 years), good Eastern Cooperative Oncology Group Performance Status (ECOG PS) score, programmed death-ligand 1 tumor proportion score (PD-L1 TPS) of ≥ 50%, absence of bone metastasis, and presence of immune-related skin toxicity, which is an immune-related adverse event, were correlated with good PFS. Moreover, good ECOG PS score, PD-L1 TPS of ≥ 50%, absence of bone metastasis, and presence of skin toxicity were correlated with good OS.ConclusionsThe 4-year survival rate was 17.9%. Good ECOG PS score, PD-L1 TPS of ≥ 50%, absence of bone metastasis, and presence of skin toxicity were correlated with good PFS and OS.  相似文献   
10.
《Cancer cell》2022,40(11):1392-1406.e7
  1. Download : Download high-res image (241KB)
  2. Download : Download full-size image
  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号